HK1001471A1 - Use of 1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the preparation of medicaments for the treatment of cerebral and neurona - Google Patents

Use of 1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the preparation of medicaments for the treatment of cerebral and neurona

Info

Publication number
HK1001471A1
HK1001471A1 HK98100449A HK98100449A HK1001471A1 HK 1001471 A1 HK1001471 A1 HK 1001471A1 HK 98100449 A HK98100449 A HK 98100449A HK 98100449 A HK98100449 A HK 98100449A HK 1001471 A1 HK1001471 A1 HK 1001471A1
Authority
HK
Hong Kong
Prior art keywords
neurona
naphthylethyl
tetrahydropyridine
trifluoromethylphenyl
medicaments
Prior art date
Application number
HK98100449A
Other languages
English (en)
Inventor
Francois Xavier Coude
Jacqueline Fournier
Umberto Guzzi
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of HK1001471A1 publication Critical patent/HK1001471A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK98100449A 1990-05-22 1998-01-20 Use of 1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the preparation of medicaments for the treatment of cerebral and neurona HK1001471A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9006399A FR2662355B1 (fr) 1990-05-22 1990-05-22 Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Publications (1)

Publication Number Publication Date
HK1001471A1 true HK1001471A1 (en) 1998-06-19

Family

ID=9396855

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98100449A HK1001471A1 (en) 1990-05-22 1998-01-20 Use of 1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the preparation of medicaments for the treatment of cerebral and neurona

Country Status (17)

Country Link
US (3) US5229389A (xx)
EP (2) EP0458696B1 (xx)
JP (2) JP2618115B2 (xx)
KR (1) KR0181330B1 (xx)
AT (2) ATE207747T1 (xx)
BR (1) BR9105015A (xx)
CA (2) CA2365832C (xx)
CY (1) CY2283B1 (xx)
DE (2) DE69132797T2 (xx)
DK (2) DK0655247T3 (xx)
FR (1) FR2662355B1 (xx)
HK (1) HK1001471A1 (xx)
HU (1) HU208922B (xx)
IE (1) IE911707A1 (xx)
IL (3) IL98175A (xx)
TW (1) TW216771B (xx)
ZA (1) ZA913865B (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0192386A (ja) * 1987-10-05 1989-04-11 Hitachi Ltd 密閉循環型吸収式冷凍機及び吸収式冷凍機用吸収液
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
US5618822A (en) * 1990-05-23 1997-04-08 Sanofi N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them
US5557209A (en) * 1990-12-20 1996-09-17 Hewlett-Packard Company Identification of pin-open faults by capacitive coupling through the integrated circuit package
FR2690158B1 (fr) * 1992-04-17 1994-07-22 Sanofi Elf Nouveau derive arylpiperidinique, procede pour sa preparation et compositions pharmaceutiques le contenant.
FR2702656B1 (fr) * 1993-03-18 1995-06-16 Sanofi Elf Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs.
US5698565A (en) * 1995-06-09 1997-12-16 Hoffmann-La Roche Inc. Use of phenoxy-pyridine derivatives
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
EE04177B1 (et) * 1995-10-26 2003-12-15 Sanofi 1-(2-naft-2-üületüül)-4-(3-trifluorometüülfenüül)-1,2,3,6-tetrahüdropüridiini kasutamine ravimite valmistamiseks amüotroofilise lateraalskleroosi raviks
FR2740343B1 (fr) * 1995-10-26 1999-01-22 Sanofi Sa Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
EP0890105B1 (en) * 1996-03-29 2006-11-22 The Trustees Of Boston University Methods related to Alzheimer's disease for diagnosis, manufacture of medicaments and screening of substances and beta-amyloid related peptides
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
FR2757161B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa Diphenylalkyl-tetrahydropyridines
FR2757510B1 (fr) * 1996-12-23 2000-01-07 Sanofi Sa Forme microparticulaire d'un derive de tetrahydropyridine
FR2757512B1 (fr) 1996-12-24 1999-03-12 Sanofi Sa Utilisation de benzoylalkyl-1-1,2,3,6-tetrahydropyridines
WO1998033502A1 (fr) * 1997-02-03 1998-08-06 Sanofi-Synthelabo Utilisation du 1-[4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl)ethane pour la preparation de medicaments destines aux traitements de troubles cerebraux et neuronaux
FR2762514B1 (fr) 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
FR2763847B1 (fr) * 1997-05-28 2003-06-06 Sanofi Sa Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
CO4980891A1 (es) * 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
FR2771007B1 (fr) * 1997-11-14 2000-12-01 Sanofi Sa Association de principes actifs pour le traitement de la demence senile du type alzheimer
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
TWI237035B (en) * 1998-07-24 2005-08-01 Polyplastics Co Polyacetal copolymer
KR101130212B1 (ko) * 2002-03-27 2012-04-13 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 사용법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2639226B1 (fr) * 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Also Published As

Publication number Publication date
AU7713391A (en) 1991-11-28
CA2042974A1 (en) 1991-11-22
ZA913865B (en) 1992-02-26
CA2042974C (en) 2002-09-17
HU911729D0 (en) 1991-12-30
FR2662355A1 (fr) 1991-11-29
IE911707A1 (en) 1991-12-04
DE69132797T2 (de) 2002-05-29
CA2365832C (en) 2007-08-07
FR2662355B1 (fr) 1994-11-10
AU636488B2 (en) 1993-04-29
DE69115989D1 (de) 1996-02-15
US5229389A (en) 1993-07-20
KR0181330B1 (ko) 1999-03-20
IE20011078A1 (en) 2002-03-20
JPH09132535A (ja) 1997-05-20
JP2618115B2 (ja) 1997-06-11
EP0655247B1 (fr) 2001-10-31
IL112167A (en) 1996-01-31
CY2283B1 (en) 2003-07-04
DE69132797D1 (de) 2001-12-06
IL112167A0 (en) 1995-03-15
IL98175A (en) 1996-01-19
BR9105015A (pt) 1993-05-25
HUT59824A (en) 1992-07-28
TW216771B (xx) 1993-12-01
DK0458696T3 (da) 1996-05-20
JP2954029B2 (ja) 1999-09-27
CA2365832A1 (en) 1991-11-23
EP0458696A2 (fr) 1991-11-27
US5270320A (en) 1993-12-14
ATE132369T1 (de) 1996-01-15
HU208922B (en) 1994-02-28
EP0458696B1 (fr) 1996-01-03
DK0655247T3 (da) 2002-02-18
JPH04226917A (ja) 1992-08-17
EP0458696A3 (en) 1992-03-18
KR910019617A (ko) 1991-12-19
ATE207747T1 (de) 2001-11-15
IL98175A0 (en) 1992-06-21
EP0655247A1 (fr) 1995-05-31
DE69115989T2 (de) 1996-08-22
US5468753A (en) 1995-11-21

Similar Documents

Publication Publication Date Title
HK1001471A1 (en) Use of 1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the preparation of medicaments for the treatment of cerebral and neurona
DE3889087D1 (de) Integrierter Tintenspritzdruckkopf und Verfahren zu dessen Herstellung.
DE3886768D1 (de) Vorrichtung zum herstellen von kunststoff-formteilen und verwendung der vorrichtung.
DE3582572D1 (de) Verfahren und vorrichtung zum herstellen eines schichtkoerpers.
DE68918663D1 (de) Verfahren zur Herstellung eines Tintenstrahldruckkopfes.
PT93333A (pt) Processo de preparacao de uma composicao biocida sinergica e de tratamento usando a referida composicao
DE69534002D1 (de) Verwendung von Phosphatidylserinen zur Herstellung eines Arzneimittels zur Verbesserung der Gehirntätigkeit
DE3889712D1 (de) Kunststofflochplatte für einen Tintenstrahldruckkopf und Herstellungsverfahren.
DE58907944D1 (de) Verfahren und Vorrichtung zum Herstellen von hochverdichteten zylindrischen Presslingen aus losem Halmgut.
DE68911686D1 (de) Vorrichtung und verfahren zur messung der aktivität von radioaktiven mustern, die mehrere radioaktive isotope enthalten, ohne separate bestimmung des löschniveaus.
DE3886461D1 (de) Verfahren und vorrichtung zum regulieren des einspritzdruckes einer spritzgiessmaschine.
EP1179588A4 (en) HUMAN BRAIN-SPECIFIC CARBOXYPEPTIDASE
DE58904328D1 (de) Verfahren zur desinfektion von medizinischen abformmassen.
DE68905837D1 (de) 2-(alkyl-cyclohexyl)-1-propanol, verfahren zu dessen herstellung und ihn enthaltende riechstoffzusammensetzung.
DE59304087D1 (de) Placentaextrakt und Verfahren zu seiner Herstellung
DE3889043D1 (de) N-(substituiertes Alkyliden)-1,2,3,4-tetrahydro-9-acridinamine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
DE68920880D1 (de) 1-amino-5-halogenouracile, verfahren zu deren herstellung und diese enthaltende cns-depressiva.
PT79928A (de) Verfahren zur herstellung von 1,3,2-dioxaborinan und von bioziden verbindungen die sie enthalten
DE58905617D1 (de) Verfahren zur Überwachung und/oder Regelung eines Spritzgiessprozesses.
ATA271985A (de) Verfahren zur herstellung von n-alkyl/en/-n-/o,o- disubstituierten thiophosphoryl/-n'n'disubstituierten-glycinamiden und diese verbindungen enthaltende akarizide, insektizide und fungizide mittel
ATA234689A (de) Neue 2-carbonyl substituierte n,n'-di(trimethoxybenzoyl)piperazine, verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
DE3870912D1 (de) 4,4'-(perfluorisopropyliden)dicyclohexanol, dessen abkoemmling und verfahren zur herstellung davon.
DE59002586D1 (de) Verfahren und vorrichtung zur individuellen herstellung eines zahnersatzteils.
ATE104283T1 (de) N-(substituiertes alkyliden)-1,2,3,4-tetrahydro-9-acridinamine, verfahren zu ihrer herstellung und ihre verwendung als medikamente.

Legal Events

Date Code Title Description
PF Patent in force
CHPA Change of a particular in the register (except of change of ownership)
PE Patent expired

Effective date: 20110520